Cytokinetics Announces Positive Topline Results From MAPLE-HCM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Stifel on Cytokinetics (CYTK): 'we remain confident in a best-in-class opportunity for aficamten'
May 13, 2025 8:26 AM EDTStifel on Cytokinetics (NASDAQ: CYTK): 'we remain confident in a best-in-class opportunity for aficamten'
The analyst comments "CYTK announced that MAPLE-HCM achieved its primary endpoint, with aficamten demonstrating superiority to beta-blockers in obstructive-HCM. Details are limited (saving it for medical meeting), but at a high-level sound... More
